![Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine](https://oncodaily.com/pub/uploads/2024/04/IMG_1903-1.jpeg)
Photo taken from Howard McLeod/LinkedIn
May 1, 2024, 04:54
Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine
Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:
“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”
Additional information
Source: Howard McLeod/LinkedIn
Aug 11, 2024, 08:04
Aug 11, 2024, 07:48
Aug 11, 2024, 06:38
Aug 11, 2024, 05:36